# An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease

> **NCT02485899** · PHASE1,PHASE2 · COMPLETED · sponsor: **BioMarin Pharmaceutical** · enrollment: 23 (actual)

## Conditions studied

- Jansky-Bielschowsky Disease
- Batten Disease
- Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2
- CLN2 Disease
- CLN2 Disorder

## Interventions

- **BIOLOGICAL:** BMN 190
- **DEVICE:** Intracerebroventricular (ICV) access device

## Key facts

- **NCT ID:** NCT02485899
- **Lead sponsor:** BioMarin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2020-12-10
- **Final completion:** 2020-12-10
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2022-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02485899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02485899, "An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02485899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*